Presurgery Plus Postsurgery Immunotherapy Ups Survival in NSCLC

Adding the PD-L1 inhibitor durvalumab to chemotherapy before and after surgery led to improved pathological complete response rates and event-free survival in patients with untreated, operable non–small cell lung cancer, according to interim results from the AEGEAN trial. Researchers noted that administering immunotherapy prior to surgery may help in developing more tailored adjuvant treatments based on patients’ responses and tumor characteristics.